For the Inventor, By the Inventor

Enter assignee name

Pittsburgh, PA, United States of America

Cellomics, Inc.

USPTO Granted Patents = 53

% Expired Patents = 13.2

EPO Patents = 6

Trademarks = 6

Forward Citations = 1,908

Loading Chart...

Loading Chart...

57 inventors (with patents filed for the assignee):

R Terry Dunlay (17 out of 18 patents)

D Lansing Taylor (11 out of 23 patents)

Kenneth A Giuliano (9 out of 13 patents)

4. Dirk John VandenBerg, Iii (7 out of 16 patents)

5. Richik Niloy Ghosh (7 out of 7 patents)

6. Keith Rao Heffley (7 out of 8 patents)

7. Kim Ippolito (6 out of 9 patents)

8. Albert H Gough (6 out of 10 patents)

9. Ravi Kapur (5 out of 7 patents)

10. Monica Tomaszewski (4 out of 5 patents)

11. Michael Andrew Sipe (4 out of 29 patents)

12. Richard A Rubin (4 out of 5 patents)

13. Jeffrey Robert Haskins (3 out of 3 patents)

14. Paul J Sammak (3 out of 11 patents)

15. Dirk John Vandenberg, Iii (3 out of 3 patents)

Core Competencies:

Automated Imaging

Neuronal Profiling

Predictive Toxicity

Image Analysis

Fluorescence Readers

Microbead Testing

Synthetic DNA

Cell Array Methods

Environmental Chamber

Cell Count

Optical Systems

Artificial Intelligence

53 patents: Sort by Forward Citations

1. 12529645 - Systems and methods for autofocus and automated cell count using artificial intelligence (2026-01-20),

2. 10393725 - Automated imaging of chromophore labeled samples (2019-08-27),

3. 10353130 - Optic homogenizer (2019-07-16),

4. 10274715 - Image-based laser autofocus system (2019-04-30),

5. 10234445 - Automated imaging of chromophore labeled samples (2019-03-19),

6. 9683939 - Automated imaging of chromophore labeled samples (2017-06-20),

7. 9400365 - Optical quickmount (2016-07-26),

8. 9201062 - Predicting toxicity of a compound over a range of concentrations (2015-12-01),

9. 9128046 - Slide holder assembly for comet assay (2015-09-08),

10. 9075228 - Optical quickmount (2015-07-07),

11. 8860797 - Integrated calibration sample bay for fluorescence readers (2014-10-14),

12. 8818070 - Predicting toxicity of a compound over a range of concentrations (2014-08-26),

13. 8649981 - Automated method and system for setting image analysis parameters to control image analysis operations (2014-02-11),

14. 8259170 - Integrated calibration sample bay for fluorescence readers (2012-09-04),

15. 8121383 - Automated method and system for setting image analysis parameters to control image analysis operations (2012-02-21),

Company Overview

Cellomics, Inc., based in Pittsburgh, PA, specializes in cell-based screening technologies that enhance drug discovery and development processes. The company focuses on automated imaging and advanced image analysis techniques to facilitate neuronal profiling and predictive toxicity assessments. Their innovative solutions, including fluorescence readers and microbead testing, support researchers in various fields by providing precise and efficient methods for analyzing cellular responses. Cellomics is committed to advancing the understanding of cellular behavior through cutting-edge technology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

53 Patents

#54 in Pittsburgh, PA

#247 in Pennsylvania

#6,672 in US

#13,348 in the World

Pittsburgh, PA, United States of America

Cellomics, Inc.

Forward Citations = 1,908

57 inventors:

R Terry Dunlay (17 out of 18 patents)

D Lansing Taylor (11 out of 23 patents)

Kenneth A Giuliano (9 out of 13 patents)

4. Dirk John VandenBerg, Iii (7 out of 16 patents)

5. Richik Niloy Ghosh (7 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cellomics, Inc.. Retrieved from https://idiyas.com/company/cellomics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…